Prostaglandins Regulate Invasive, Collective Border Cell Migration
Overview
Molecular Biology
Affiliations
While prostaglandins (PGs), short-range lipid signals, regulate single cell migration, their roles in collective migration remain unclear. To address this, we use border cell migration, an invasive, collective migration that occurs during Stage 9 of oogenesis. Pxt is the cyclooxygenase-like enzyme responsible for PG synthesis. Loss of Pxt results in both delayed border cell migration and elongated clusters, whereas somatic Pxt knockdown causes delayed migration and compacted clusters. These findings suggest PGs act in both the border cells and nurse cells, the substrate on which the border cells migrate. As PGs regulate the actin bundler Fascin, and Fascin is required for on-time migration, we assessed whether PGs regulate Fascin to promote border cell migration. Coreduction of Pxt and Fascin results in delayed migration and elongated clusters. The latter may be due to altered cell adhesion, as loss of Pxt or Fascin, or coreduction of both, decreases integrin levels on the border cell membranes. Conversely, integrin localization is unaffected by somatic knockdown of Pxt. Together these data lead to the model that PG signaling controls Fascin in the border cells to promote migration and in the nurse cells to maintain cluster cohesion.
Functional characterization of eicosanoid signaling in development.
Fujinaga D, Nolan C, Yamanaka N bioRxiv. 2025; .
PMID: 39868285 PMC: 11761813. DOI: 10.1101/2025.01.13.632770.
Mellentine S, Brown H, Ramsey A, Li J, Tootle T Front Cell Dev Biol. 2024; 11:1257751.
PMID: 38283991 PMC: 10811798. DOI: 10.3389/fcell.2023.1257751.
Berg C, Sieber M, Sun J Genetics. 2023; 226(1).
PMID: 38000906 PMC: 10763546. DOI: 10.1093/genetics/iyad183.
Mellentine S, Ramsey A, Li J, Brown H, Tootle T bioRxiv. 2023; .
PMID: 37425965 PMC: 10327004. DOI: 10.1101/2023.06.23.546291.
Downregulation of fascin induces collective cell migration in triple‑negative breast cancer.
Yamamoto Y, Hayashi Y, Sakaki H, Murakami I Oncol Rep. 2023; 50(2).
PMID: 37326137 PMC: 10308486. DOI: 10.3892/or.2023.8587.